Multiple myeloma

We have established and are leading the International Multiple Myeloma rESEarch (IMMEnSE) consortium, that brings together several international clinical and research institutions with the aim to investigate genetic epidemiology and pharmacogenetics of multiple myeloma (MM) in one of the largest populations of MM patients existing up to date. At present we have collected about 1500 samples of cases and a similar number of controls. In this context we perform studies on susceptibility SNPs, both following a candidate gene approach and following up findings by a GWAS that has been recently published (in collaboration with the Division of Molecular Genetic Epidemiology), and studies on the impact of SNPs on response to treatment and survival. We are also collecting samples of cases with monoclonal gammopathy of undetermined significance (MGUS), the benign precursor of MM, with the aim of identifying SNPs predisposing to the transition from MGUS to MM.

to top